Earnings Per Share (EPS) of $1.59, surpassing the estimated $1.25, indicating a 27.20% earnings surprise.
Revenue reached approximately $589.1 million, exceeding forecasts and marking a year-over-year increase.
ICU Medical Inc. (NASDAQ:ICUI) is a key player in the medical products industry, known for its innovative infusion therapy, oncology, and critical care products. The company competes with other medical device manufacturers, striving to deliver high-quality solutions to healthcare providers. On November 12, 2024, ICUI reported its third-quarter earnings, showcasing strong financial performance.
ICUI reported earnings per share (EPS) of $1.59, surpassing the estimated $1.25. This represents a 27.20% earnings surprise, as highlighted by Zacks. The company has consistently outperformed consensus EPS estimates over the past four quarters, demonstrating its ability to exceed market expectations. In the previous quarter, ICUI also delivered an impressive EPS of $1.56, beating the anticipated $0.98.
The company achieved a revenue of approximately $589.1 million, exceeding the forecasted $574.7 million. This marks a 0.92% increase over the Zacks Consensus Estimate. ICUI’s revenue growth is evident, with a rise from $553.31 million in the same period last year. The company has consistently surpassed consensus revenue estimates in each of the last four quarters, reflecting its robust performance.
ICUI’s price-to-sales ratio of 1.83 indicates investor confidence, as they are willing to pay $1.83 for every dollar of sales. The enterprise value to sales ratio of 2.37 further reflects the company’s total valuation relative to its sales. Additionally, the enterprise value to operating cash flow ratio of 21.76 provides insight into the company’s valuation compared to its cash flow from operations.
ICUI maintains a debt-to-equity ratio of 0.78, indicating a moderate level of debt relative to its equity. The current ratio of 2.29 suggests that the company has a strong ability to cover its short-term liabilities with its short-term assets. This financial stability positions ICUI well within the Zacks Medical – Products industry, highlighting its consistent growth and performance.
